| Metric | Value ($ M) | Q2 FY25 |
|---|---|---|
| Revenue | 340.10 | 9.5% |
| Total Income | 340.10 | 9.5% |
| Expenditure | 335.88 | 10.4% |
| PBT | -26.31 | 61.7% |
| Net Profit | 12.51 | 123.5% |
| OPM | 1.24% | 0.77pp |
| NPM | 3.68% | 20.79pp |
| EPS | 0.05 | 119.2% |
Curaleaf Reports Q2 2026 Results: Revenue Grows 10% YoY to $340 Million
06 Aug 2026 · 6 Aug, 3:41 pm
Summary
Curaleaf Holdings, Inc. announced its financial results for the second quarter ended June 30, 2026, reporting net revenue of $340 million, a 10% increase compared to the prior year. The company maintained a strong gross profit margin of 50% and reported net income from continuing operations of $12.5 million. Adjusted EBITDA stood at $70.1 million with a margin of 20.6%. Management highlighted the 'Built for Growth' strategy gaining traction, with both domestic and international segments showing growth, and noted significant operational achievements including retail expansion and new product launches.
Key Highlights
- 1
Curaleaf reported second quarter 2026 net revenue of $340 million, representing a 10% year-over-year increase.
- 2
The company achieved a gross profit margin of 50% in the second quarter of 2026.
- 3
Second quarter 2026 net income from continuing operations was $12.5 million, or $0.05 per share.
- 4
Adjusted EBITDA for the second quarter of 2026 was $70.1 million, with an adjusted EBITDA margin of 20.6%.
- 5
International revenue grew by 26% year-over-year in the second quarter of 2026.
- 6
The company expanded its retail footprint in Florida to 73 dispensaries and launched its ultra-premium flower brand, Dark Heart, across 11 states.
Management Comments
Boris Jordan
Our second quarter results reinforce that our ‘Built for Growth’ strategy, a disciplined framework focused on customer centricity, brand building, and operational excellence is gaining traction across the business. Second quarter revenue of $340 million grew 10% compared to last year, bolstered by both our domestic and international segments that grew 7% and 26%, respectively. Our U.S. business has clearly regained momentum. This was our second consecutive quarter of domestic year-over-year growth, and an important proof point that our reset is taking hold in a durable way. Gross margin was 50% and adjusted EBITDA was $70 million, representing a 21% margin. Net income from continuing operations was $12.5 million and we ended the quarter with $107 million in cash on the balance sheet. We have a strong, cohesive team aligned around one common goal: making Curaleaf the global leader in cannabis. While there is still work ahead and significant opportunity to capture, we are firmly on the right path – with the team, strategy, and operating discipline to lead the next phase of cannabis.
Informational and educational content only. Not investment advice.